NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

VEEV

290.97

+1.73%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

VEEV

290.97

+1.73%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

VEEV

290.97

+1.73%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

VEEV

290.97

+1.73%↑

NVS

117.16

-0.7%↓

ABT

125.67

-0.1%↓

MDT

92.35

+0.27%↑

ELV.US

280.42

-5.39%↓

VEEV

290.97

+1.73%↑

Search

Johnson and Johnson

Open

SectorGezondheidszorg

168.71 -0.3

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

168.84

Max

169.97

Belangrijke statistieken

By Trading Economics

Inkomsten

7.6B

11B

Verkoop

1.9B

24B

K/W

Sectorgemiddelde

17.579

38.156

EPS

2.77

Dividendrendement

3.07

Winstmarge

50.24

Werknemers

138,100

EBITDA

-9.1B

6.5B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+4.29% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.07%

2.50%

Volgende Winsten

14 okt 2025

Volgende dividenddatum

9 sep 2025

Volgende Ex Dividend datum

26 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

18B

395B

Vorige openingsprijs

169.01

Vorige sluitingsprijs

168.71

Nieuwssentiment

By Acuity

23%

77%

48 / 375 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Johnson and Johnson Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jul 2025, 16:47 UTC

Winsten

J&J Raises Full-Year Outlook After Beating 2Q Expectations -- Update

16 jul 2025, 18:08 UTC

Marktinformatie
Winsten

J&J's Orthopedic Decline Likely Hinges on Company-Specific Challenges -- Market Talk

16 jul 2025, 17:27 UTC

Marktinformatie
Winsten

J&J Expects Medical Devices Sales Boost from Cardiovascular -- Market Talk

16 jul 2025, 17:17 UTC

Marktinformatie
Winsten

J&J Sees Growth Across Portfolio Offsetting Loss of Stelara -- Market Talk

16 jul 2025, 16:34 UTC

Marktinformatie
Winsten

J&J Sees Lower Tariff Risk for the Year -- Market Talk

16 jul 2025, 13:27 UTC

Winsten

Johnson & Johnson Beats Earnings Estimates. CFO Says It Can Do Any Deal It Wants. -- Barrons.com

16 jul 2025, 10:32 UTC

Winsten

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 jul 2025, 10:22 UTC

Winsten

Correct: Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson Beats Earnings Estimates. Financial Chief Says It Can Do Any Deal It Wants. -- Barrons.com

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.63-$10.73 Vs Prior Outlook $10.50-$10.70 >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson Raises 2025 View To Sales $93.2B-$93.6B Vs Prior Outlook $91B-$91.8B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson Raises 2025 View To Adj EPS $10.80-Adj EPS $10.90 Vs Prior Outlook $10.50-$10.70 >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson: Increasing 2025 Operational Sales Growth to Be in Range of 4.5%-5% Vs Prior Range 3.3%-4.3% >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson Now Sees 2025 Operational Sales of $92.7B-$93.1B Vs Prior Outlook $91.6B-$92.4B>JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson: Our Portfolio and Pipeline Position Us for Elevated Growth in Second Half of Year >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson Now Sees 2025 Adjusted Operational Sales Growth of 3.2%-3.7% Vs Prior Outlook 2%-3% >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson: 2Q MedTech Business Delivered Operational Sales Growth of 6.1%, Driven Primarily by Strength in Electrophysiology Products and Abiomed, Wound Closure Pdts and Improved Performance in Surgical Vision >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q Worldwide MedTech Sales $8.54B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Growth Driven by Darzalex, Carvykti, Rybrevant, Lazcluze, Tremfya and Spravato >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson: 2Q Innovative Medicine Operational Sales Grew 3.8% With 13 Brands Growing Double Digits >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q International Sales $23.74B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q U.S. Sales $13.54B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q Sales $23.74B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q EPS $2.29 >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q Adj EPS $2.77 >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q Orthopaedics Sales $2.3B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q Orthopaedics Sales $2.31B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q International Sales $10.2B >JNJ

16 jul 2025, 10:20 UTC

Winsten

Johnson & Johnson 2Q Worldwide Innovative Medicine Sales $15.2B >JNJ

Peer Vergelijking

Prijswijziging

Johnson and Johnson Prognose

Koersdoel

By TipRanks

4.29% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 176.35 USD  4.29%

Hoogste 190 USD

Laagste 160 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Johnson and Johnson - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

19 ratings

9

Buy

10

Hold

0

Sell

Technische score

By Trading Central

154.93 / 155.895Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

48 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.